Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J Ultram Titration Relabeling Should Not Block Generics, Apotex Argues

Executive Summary

Apotex' citizen petition requesting approval of generic Ultram argues that Johnson & Johnson did not make labeling changes for safety or efficacy reasons

You may also be interested in...



36Ultram Generics Will Reference 50 mg, But Not 25 Mg, Titration Schedule

FDA is approving Ultram (tramadol) generics with labeling that includes the 50 mg titration regimen, but not the protected 25 mg titration schedule

36Ultram Generics Will Reference 50 mg, But Not 25 Mg, Titration Schedule

FDA is approving Ultram (tramadol) generics with labeling that includes the 50 mg titration regimen, but not the protected 25 mg titration schedule

Ultram Generic Approval For Acute Pain Would Avoid Protected Label – Teva

Teva is seeking approval for a generic version of Johnson & Johnson's Ultram (tramadol) only for acute pain in order to circumvent the brand's patent-protected titration schedule

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS038867

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel